Apple Turns 50: From Garage Startup to AI Crossroads 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
CRANBURY, N.J., Sept. 22, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on September 28, 2016 at 3:05pm ET.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: MWW PR Sean Conley [email protected] (646) 381-9096
